p5i

Property	Value
?:abstract	Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with substantial cardiovascular implications Although infection with SARS-CoV-2 is usually mild in children, some children later develop a severe inflammatory disease that can have manifestations similar to toxic shock syndrome or Kawasaki disease This syndrome has been defined by the US Centers for Disease Control and Prevention as multisystem inflammatory syndrome in children Although the prevalence is unknown, >600 cases have been reported in the literature Multisystem inflammatory syndrome in children appears to be more common in Black and Hispanic children in the United States Multisystem inflammatory syndrome in children typically occurs a few weeks after acute infection and the putative etiology is a dysregulated inflammatory response to SARS-CoV-2 infection Persistent fever and gastrointestinal symptoms are the most common symptoms Cardiac manifestations are common, including ventricular dysfunction, coronary artery dilation and aneurysms, arrhythmia, and conduction abnormalities Severe cases can present as vasodilatory or cardiogenic shock requiring fluid resuscitation, inotropic support, and in the most severe cases, mechanical ventilation and extracorporeal membrane oxygenation Empirical treatments have aimed at reversing the inflammatory response using immunomodulatory medications Intravenous immunoglobulin, steroids, and other immunomodulatory agents have been used frequently Most patients recover within days to a couple of weeks and mortality is rare, although the medium- and long-term sequelae, particularly cardiovascular complications, are not yet known This review describes the published data on multisystem inflammatory syndrome in children, focusing on cardiac complications, and provides clinical considerations for cardiac evaluation and follow-up Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with substantial cardiovascular implications. Although infection with SARS-CoV-2 is usually mild in children, some children later develop a severe inflammatory disease that can have manifestations similar to toxic shock syndrome or Kawasaki disease. This syndrome has been defined by the US Centers for Disease Control and Prevention as multisystem inflammatory syndrome in children. Although the prevalence is unknown, >600 cases have been reported in the literature. Multisystem inflammatory syndrome in children appears to be more common in Black and Hispanic children in the United States. Multisystem inflammatory syndrome in children typically occurs a few weeks after acute infection and the putative etiology is a dysregulated inflammatory response to SARS-CoV-2 infection. Persistent fever and gastrointestinal symptoms are the most common symptoms. Cardiac manifestations are common, including ventricular dysfunction, coronary artery dilation and aneurysms, arrhythmia, and conduction abnormalities. Severe cases can present as vasodilatory or cardiogenic shock requiring fluid resuscitation, inotropic support, and in the most severe cases, mechanical ventilation and extracorporeal membrane oxygenation. Empirical treatments have aimed at reversing the inflammatory response using immunomodulatory medications. Intravenous immunoglobulin, steroids, and other immunomodulatory agents have been used frequently. Most patients recover within days to a couple of weeks and mortality is rare, although the medium- and long-term sequelae, particularly cardiovascular complications, are not yet known. This review describes the published data on multisystem inflammatory syndrome in children, focusing on cardiac complications, and provides clinical considerations for cardiac evaluation and follow-up.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C0002940> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C0036980> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C0161816> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C0232219> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C0242973> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C0426576> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C0476474> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C0543419> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C1155266> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C1457887> <https://research.tib.eu/covid-19/entity/67243p5i_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Alsaied%2C_T.%3B_Tremoulet%2C_A._H.%3B_Burns%2C_J._C.%3B_Saidi%2C_A.%3B_Dionne%2C_A.%3B_Lang%2C_S._M.%3B_Newburger%2C_J._W.%3B_de_Ferranti%2C_S.%3B_Friedman%2C_K._G.> <https://research.tib.eu/covid-19/entity/Alsaied%2C_Tarek%3B_Tremoulet%2C_Adriana_H%3B_Burns%2C_Jane_C%3B_Saidi%2C_Arwa%3B_Dionne%2C_Audrey%3B_Lang%2C_Sean_M%3B_Newburger%2C_Jane_W%3B_de_Ferranti%2C_Sarah%3B_Friedman%2C_Kevin_G>
?:journal	Circulation
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/67243p5i_HAS_C0275518_PRECEDES_C5389369> <https://research.tib.eu/covid-19/entity/67243p5i_HAS_C5203676_CAUSES_C0009450>
?:source	WHO
?:title	Review of Cardiac Involvement in Multisystem Inflammatory Syndrome in Children
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1066978 #917837
?:year	2021

Property

Value

?:abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with substantial cardiovascular implications Although infection with SARS-CoV-2 is usually mild in children, some children later develop a severe inflammatory disease that can have manifestations similar to toxic shock syndrome or Kawasaki disease This syndrome has been defined by the US Centers for Disease Control and Prevention as multisystem inflammatory syndrome in children Although the prevalence is unknown, >600 cases have been reported in the literature Multisystem inflammatory syndrome in children appears to be more common in Black and Hispanic children in the United States Multisystem inflammatory syndrome in children typically occurs a few weeks after acute infection and the putative etiology is a dysregulated inflammatory response to SARS-CoV-2 infection Persistent fever and gastrointestinal symptoms are the most common symptoms Cardiac manifestations are common, including ventricular dysfunction, coronary artery dilation and aneurysms, arrhythmia, and conduction abnormalities Severe cases can present as vasodilatory or cardiogenic shock requiring fluid resuscitation, inotropic support, and in the most severe cases, mechanical ventilation and extracorporeal membrane oxygenation Empirical treatments have aimed at reversing the inflammatory response using immunomodulatory medications Intravenous immunoglobulin, steroids, and other immunomodulatory agents have been used frequently Most patients recover within days to a couple of weeks and mortality is rare, although the medium- and long-term sequelae, particularly cardiovascular complications, are not yet known This review describes the published data on multisystem inflammatory syndrome in children, focusing on cardiac complications, and provides clinical considerations for cardiac evaluation and follow-up
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with substantial cardiovascular implications. Although infection with SARS-CoV-2 is usually mild in children, some children later develop a severe inflammatory disease that can have manifestations similar to toxic shock syndrome or Kawasaki disease. This syndrome has been defined by the US Centers for Disease Control and Prevention as multisystem inflammatory syndrome in children. Although the prevalence is unknown, >600 cases have been reported in the literature. Multisystem inflammatory syndrome in children appears to be more common in Black and Hispanic children in the United States. Multisystem inflammatory syndrome in children typically occurs a few weeks after acute infection and the putative etiology is a dysregulated inflammatory response to SARS-CoV-2 infection. Persistent fever and gastrointestinal symptoms are the most common symptoms. Cardiac manifestations are common, including ventricular dysfunction, coronary artery dilation and aneurysms, arrhythmia, and conduction abnormalities. Severe cases can present as vasodilatory or cardiogenic shock requiring fluid resuscitation, inotropic support, and in the most severe cases, mechanical ventilation and extracorporeal membrane oxygenation. Empirical treatments have aimed at reversing the inflammatory response using immunomodulatory medications. Intravenous immunoglobulin, steroids, and other immunomodulatory agents have been used frequently. Most patients recover within days to a couple of weeks and mortality is rare, although the medium- and long-term sequelae, particularly cardiovascular complications, are not yet known. This review describes the published data on multisystem inflammatory syndrome in children, focusing on cardiac complications, and provides clinical considerations for cardiac evaluation and follow-up.

is ?:annotates of